Lilly adds $5.3 billion in Lebanon, Indiana, taking the site to $9 billion

Eli Lilly said on May 24, 2024, that it will invest another $5.3 billion in its manufacturing site in Lebanon, Indiana, more than doubling its earlier commitment and raising the total for the site from $3.7 billion to $9 billion ^[1][3][5]. The money is aimed at making more active pharmaceutical ingredient (API) for tirzepatide, the molecule sold as Zepbound for obesity and Mounjaro for type 2 diabetes ^[1][3].

"Today's announcement tops the largest manufacturing investment in our company's history and, we believe, represents the single largest investment in synthetic medicine API manufacturing in U.S. history," said David A. Ricks, Lilly's chair and CEO ^[1][3][5]. Lilly said that since 2020 it has committed more than $16 billion to build new plants in the US and Europe, plus $1.2 billion to upgrade existing Indianapolis facilities and a recent purchase of an injectable plant in Pleasant Prairie, Wisconsin, from Nexus Pharmaceuticals — more than $18 billion in total ^[1][5].

The numbers behind the plant

Lilly broke ground at the Lebanon site, inside Indiana's LEAP Research and Innovation District, in April 2023 and has turned much of the nearly 600-acre complex into an active construction zone ^[1][2]. The company expects to begin making medicines there toward the end of 2026, with operations scaling up through 2028 ^[1][5][6].

The expansion adds 200 full-time jobs for engineers, scientists, operators and lab technicians, bringing the expected total to about 900 when the site is fully running, plus more than 5,000 construction jobs during development ^[1][2][5]. Indiana is contributing road, water and utility work and incentives: up to $500,000 in training grants, up to $20 million in redevelopment tax credits and $15 million for road improvements, plus a revised 30-year Innovation Development District award valued at an estimated $1.2 billion in tax rebates ^[2]. The state's release describes the capital addition as "an additional $5.2 billion" in one passage while citing the $5.3 billion figure and $9 billion total elsewhere; Lilly's own release consistently says $5.3 billion ^[1][2].

The site's budget grew in steps. Lilly first announced $2.1 billion and up to 500 jobs at LEAP in May 2022, then added $1.6 billion and 200 jobs at the April 2023 groundbreaking ^[2].

Why it matters for patients

At the time of the announcement, Zepbound and Mounjaro were in shortage in the US, with limited availability expected across most doses through the second quarter of 2024 ^[3]. Lilly told investors in April 2024 that it expected Zepbound supply to remain "quite tight" in the near and mid term as it ramps up capacity ^[3]. Zepbound launched in the US in late 2023, and Lilly has since sold more than 1.2 million prescriptions of the drugs, according to IQVIA data cited by Reuters ^[3].

API is the drug substance itself — the step that comes before a medicine is put into pens or vials. More API capacity is a precondition for more finished doses, but the Lebanon plant will not produce anything until late 2026 at the earliest, so it does not change supply in 2024 ^[1][3][6]. Lilly has said its Concord, North Carolina, plant and expanded Durham facilities were expected to start increasing supplies of Zepbound and Mounjaro when they became operational in 2024 ^[3].

The announcement also signals Lilly's read on long-term demand. The company said it began expanding in 2020 based on tirzepatide research results, building capacity "at risk" before Mounjaro was approved in 2022 and Zepbound in 2023 ^[1][5]. Lilly describes tirzepatide as the only approved treatment activating two incretin hormone receptors, GIP and GLP-1 ^[1][5].

Competitors are moving too. Reuters reported that Novo Nordisk, maker of Wegovy, is taking over three sites from contract manufacturer Catalent for $11 billion ^[3], as part of Novo Holdings' $16.5 billion acquisition of the contract manufacturer ^[6].

What happens next

Key dated milestones from the sources: medicine production at Lebanon is expected to begin toward the end of 2026, with scale-up through 2028 ^[1][5][6]. Indiana's incentives remain subject to final IEDC board and state approvals and contracting ^[2]. Whether and when the added capacity ends the US shortage of tirzepatide products is not stated in these sources.